Through our advanced platform for high-throughput screening against novel drug targets in these pathways, we are developing lead compounds to treat a variety of illnesses, including cancer, muscle wasting, and neurodegenerative disease. We offer collaborative opportunities built around our novel screening technologies and our lead compounds.
Progenra announces the publication of a review highlighting deubiquitinases as novel anticancer targets.
More information...
Recent publications from the R&D team covering
Progenra's screening platforms and basic research on the ubiquitin
pathway.
More information...
web design by JOT Infomedia